

12-17-01

A
Box 500Please type a plus sign (+) inside this box → ☐12/10/01
J1025 U.S. PRO12/10/01
Jc997 U.S. PRO

UTILITY PATENT APPLICATION TRANSMITTAL <i>(only for new non-provisional applications under 37 CFR 1.53(b))</i>		Attorney Docket No. ORT-1552	
		First Named Inventor or Application Identifier DARROW, Andrew	
		Express Mail No.	ET666296585US
APPLICATION ELEMENTS <i>See MPEP Chapter 600 concerning utility patent application contents.</i>		ADDRESS TO: Assistant Commissioner for Patents BOX PATENT APPLICATION Washington, DC 20231	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (attached hereto in duplicate) 2. <input checked="" type="checkbox"/> Specification [Total Pages: 136] <i>(Preferred arrangement set forth below)</i> <ul style="list-style-type: none"> - Descriptive Title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference to Microfiche Appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (if filed) - Detailed Description - Claim(s) - Abstract of the Disclosure 3. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets: 34] 4. Oath or Declaration <ul style="list-style-type: none"> a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Unexecuted original c. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional check boxes 5 and 16)</i> <input type="checkbox"/> Deletion of Inventor(s): Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 5. <input checked="" type="checkbox"/> Incorporation by Reference (useable if Box 4c is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4c, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.		6. <input type="checkbox"/> Microfiche Computer Program (Appendix) 7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) <ul style="list-style-type: none"> a. <input checked="" type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies ACCOMPANYING APPLICATION PARTS <ul style="list-style-type: none"> 8. <input type="checkbox"/> Assignment Papers (cover sheet & document(s)) 9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <i>(when there is an assignee)</i> <input type="checkbox"/> Power of Attorney 10. <input type="checkbox"/> English Translation Document (if applicable) 11. <input checked="" type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations 12. <input type="checkbox"/> Preliminary Amendment 13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i> 14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i> 15. <input checked="" type="checkbox"/> Other: Express Mail Certification 	
16. <input checked="" type="checkbox"/> If a CONTINUING APPLICATION , check appropriate box and supply the requisite information: Amend the specification by inserting before the first line: This is a <input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-Part (CIP) of prior application No.: 09/386,642, filed 31 August 1999.			
17. If a DIVISIONAL APPLICATION , please cancel original Claims <u>N/A</u> of the prior application before calculating the filing fee.			
18. Correspondence Address: <input type="checkbox"/> Customer Number or Bar Code Label _____ or <input checked="" type="checkbox"/> Correspondence Address below: Name: Philip S. Johnson, Esq. Address: Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003, USA			
19. Telephone Contact: Please direct all telephone calls or tele-faxes to John W. Wallen, III at: Telephone: (858) 784-3239 Fax: (732) 524-2808			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED			
NAME	John W. Wallen, III, Esq. Reg. No. 35,403		
SIGNATURE		DATE	10 December 2001

FEE TRANSMITTAL	<i>Complete if Known</i>	
	Application Number	Not Assigned
	Filing Date	10 December 2001
	First Named Inventor	DARROW
	Group Art Unit	Not Assigned
	Examiner Name	Not Assigned
	Attorney Docket Number	ORT-1552


FEE CALCULATION

CLAIMS AS FILED

(1)	(2)	(3)	(4)	(5)
FOR:	NUMBER FILED	NUMBER EXTRA	RATE	BASIC FEE (\$710.00)
TOTAL CLAIMS	26 - 20 =	6	X 18.00	\$ 108.00
INDEPENDENT CLAIMS	3 - 3 =	0	X 80.00	\$ 0.00
MULTIPLE DEPENDENT CLAIMS	<input type="checkbox"/>	N/A	\$270.00	
			TOTAL FEES	\$ 818.00

METHOD OF PAYMENT

- ☒ Please charge Deposit Account No. 10-0750/ORT-1552/JWW in the amount of \$818.00. Three copies of this sheet are enclosed.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required in connection with the filing of this communication, or credit any overpayment, to Account No. 10-0750/ORT-1552/JWW. Three copies of this sheet are enclosed.

SUBMITTED BY:			<i>Complete (if applicable)</i>
Typed or Printed Name	John W. Wallen, III		Reg. No. 35,403
Signature		Date: 10 Dec. 2001	<u>Deposit Account</u> No. 10-0750

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

Applicants: Andrew L. DARROW, Jenson QI, and Patricia ANDRADE-GORDON
For: ZYMOGEN ACTIVATION SYSTEM
Filed: 10 December 2001

Express Mail Certificate


"Express Mail" mailing number: ET666296585US

Date of Deposit: 10 December 2001

I hereby certify that this complete divisional application, including complete copy of the specification pages and claims of the original application, as well as copies of the original Submission of Combined Declaration and Power of Attorney and Information Disclosure Statement, is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Amy M. Sheridan

(Typed or printed name of person mailing paper or fee)


(Signature of person mailing paper or fee)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Andrew L. DARROW, Jenson QI and Patricia ANDRADE-GORDON

Serial No.: Not Assigned

Art Unit: Not Assigned

Filed: 10 December 2001

Examiner: Not Assigned

For: ZYMOGEN ACTIVATION SYSTEM

Assistant Commissioner for Patents
BOX: Patent Applications
Washington, D.C. 20231


**REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Sir:

Submitted herewith is a computer readable form of the Sequence Listing with the appropriate statements that the computer readable and paper copies are the same.

The following statements are made as required by 37 C.F.R. 1.821(f): I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written sequence listing.

Respectfully submitted,



John W. Wallen, III
Reg. No. 35,403
Attorney for Applicant(s)

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(858) 784-3239
DATE: 10 December 2001